Predictors of response to pegylated interferon treatment in HBeAg-negative patients with chronic hepatitis B

Basit Öğe Kaydı
dc.contributor.authorGüçlü, Ertuğrul
dc.contributor.authorTuna, Nazan
dc.contributor.authorKarabay, Oğuz
dc.contributor.authorAkhan, Sıla
dc.contributor.authorBodur, Hürrem
dc.contributor.authorCeylan, Bahadır
dc.contributor.authorTütüncü, Ediz
dc.date.accessioned2020-04-30T23:21:24Z
dc.date.available2020-04-30T23:21:24Z
dc.date.issued2014
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptiondemirdal, tuna/0000-0002-9046-5666; Geyik, Mehmet Faruk/0000-0002-0906-0902; Gunduz, Alper/0000-0001-9154-844X; Karabay, Oguz/0000-0003-0502-432Xen_US
dc.descriptionWOS: 000352106600012en_US
dc.descriptionPubMed: 25500658en_US
dc.description.abstractIntroduction: Although pegylated interferons (pegIFNs) alpha-2a and alpha-2b have been used in chronic hepatitis B (CHB) treatment for many years, there are few studies concerning predictors of sustained virologic response (SVR) to pegIFN therapy. In this study, we aimed to investigate the predictors of response to pegIFN treatment in cases with HBeAg-negative CHB infection. Methodology: Seventeen tertiary care hospitals in Turkey were included in this study. Data from consecutively treated HBeAg-negative CHB patients, who received either pegIFN alpha-2a or alpha-2b, were collected retrospectively. SVR is defined as an HBV DNA concentration of less than 2,000 IU/mL six months after the completion of therapy Results: SVR was achieved in 40 (25%) of the 160 HBeAg-negative CHB patients. Viral loads in patients with SVR were lower compared to those with no SVR, beginning in the third month of treatment (p < 0.05). The number of cases with a decline of 1 log(10) IU/mL in viral load after the first month of treatment and with a serum HBV DNA level under 2,000 IU/mL after the third month of treatment was higher in cases with SVR (p < 0.05). The number of patients who had undetectable HBV DNA levels at week 48 among responders was significantly greater than among post-treatment virological relapsers (p < 0.05). Conclusions: Detection of a 1 log(10) decline in serum HBV DNA level at the first month of treatment and a serum HBV DNA level < 2000 IU/mL at the third month of therapy may be predictors of SVR.en_US
dc.identifier.doi10.3855/jidc.4953en_US
dc.identifier.endpage1608en_US
dc.identifier.issn1972-2680
dc.identifier.issue12en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1601en_US
dc.identifier.urihttps://doi.org/10.3855/jidc.4953
dc.identifier.urihttps://hdl.handle.net/20.500.12684/4189
dc.identifier.volume8en_US
dc.identifier.wosWOS:000352106600012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherJ Infection Developing Countriesen_US
dc.relation.ispartofJournal Of Infection In Developing Countriesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjecthepatitis Ben_US
dc.subjectinterferonen_US
dc.subjectsustained virological responseen_US
dc.subjectviral loaden_US
dc.titlePredictors of response to pegylated interferon treatment in HBeAg-negative patients with chronic hepatitis Ben_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
4189.pdf
Boyut:
547.4 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu